Spread the love

A study from the Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts shows that “Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.” This study was published in the June 15  2004 Genes & Development by Prof Lees JAAslanian A and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small-RNA based therapy for Human cancers:  MiRNA-144 increases the expression of tumor suppressor ARF via down regulation of its target geneThis study suggests that miR-144, by decreasing the expression of its target gene, it may inhibit the progression of cancer. Interestingly, ARF is silenced  in a number of human cancers, suggesting that activation of its expression may inhibit the progression of cancer. Together, this study suggests that pharmacological formulations encompassing “MiRNA-144  or its activators” may be used to cure human cancers.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., Small-RNA based therapy for Human cancers:  MiRNA-144 increases the expression of tumor suppressor ARF via down regulation of its target gene, 1/August/2014, 6.08 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love